Evaluating the effect of Agaricus bisporus powder intake on the vaccination response to an influenza vaccine
- Conditions
- verminderde immuunresponsDecreased immune response
- Registration Number
- NL-OMON53177
- Lead Sponsor
- niversiteit Maastricht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 105
Aged 60 years or older during influenza season 2023/2024 (in line with RIVM
guidelines)
BMI between 20 and 35 kg/m2
Willing to abstain from mushrooms other than the capsules containing a mushroom
powder as provided by us during the study period.
Willing to keep the intake of fish oil, Zinc, Selenium and (vitamin)
supplements constant
Willing to abstain from products / supplements enriched with Vitamin D
Willing to abstain from products / supplements enriched with plant sterols or
stanols
Willing to abstain from products / supplements enriched with (β)glucans or
fungi.
Willing to abstain from products / supplements that are mentioned to *boost
your immune system*
Willing to abstain from (products enriched in) pre/pro-biotics
Already received influenza vaccination in 2023
Allergy to mushrooms
Known allergic reaction to an active component or other components of the
vaccine (e.g. Chicken Eggs)
Having donated blood within one month prior to the start of the study, or
planning to donate blood during the study
Excessive alcohol use (>20 consumptions per week)
Regular use of soft and/or hard drugs
Using medication for diseases known to affect inflammation/immunity (e.g.
inhaled corticosteroids and prednisone)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method